- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01764646
Hypofractionated Radiation Therapy in Prostate Cancer
Stereotactic Body Radiation Therapy for cT1c - cT3a Prostate Cancer With a Low Risk of Nodal Metastases (≤ 20%, Roach Index): a Novalis Circle Phase II Prospective Randomized Trial
RATIONALE: It is not yet known whether extreme hypofractionation is equally safe and effective than standard radiation therapy in treating prostate cancer.
PURPOSE: This protocol presents a randomised phase II study aiming to investigate the tolerance and disease control of extreme hypofractionated Radiation Therapy for prostate cancer.
Study Overview
Status
Conditions
Detailed Description
This protocol presents a randomised phase II study aiming to investigate the tolerance and disease control of extreme hypofractionated RT for prostate cancer by delivering 5 x 7.25 Gy = 36.25 Gy over two alternative time schedules: either over 9 days (study A), or over 28 days once-a-week, the same week-day (study B).
The total dose and fractionation schedules have been chosen based on the assumption of their isoeffectivity regarding potential late rectal effects to be expected with a maximum equivalent dose of 74 Gy in 2 Gy fractions and assuming an alpha/beta = 3 Gy for the rectum.
In both arms, the prescribed dose per fraction to the urethra and the surrounding transitional zone will be dropped from 7.25 Gy to 6.5 Gy with a simultaneous integrated boost (SIB) technique. A dose of 5 x 6.5 Gy is equivalent to 31 x 2 Gy assuming an alpha/beta = 3 Gy for the urethra and equivalent to 37 x 2 Gy assuming an alpha/beta = 1.5 Gy for microscopic tumour foci in the transitional zone surrounding the urethra. The two treatment regimens chosen will each be the object of a separate phase I-II study covered by the same protocol and performed in parallel by the participating centres. Randomised assignment to either of the two studies will be introduced to avoid selection bias in treatment assignment within each centre.
OBJECTIVES:
Primary
To determine the risk of urinary, rectal and sexual acute and late toxicities rates in patients receiving two different time schedules of extreme hypofractionated radiation therapy
• Secondary
- To determine the Quality of life (EORTC QLQ-C30, Prostate cancer module EORTC QLQ-PR25) in patients receiving two different time schedules of extreme hypofractionated radiation therapy
- To determine the rate of local failure
- To determine in the two study arms the biochemical disease-free survival bDFS rate
- To determine in the two study arms the metastases-free survival rate
- To determine in the two study arms the disease-specific survival rate
OUTLINE:
This is a multicenter study.
Patients undergo extreme hypofractionated radiation therapy for prostate cancer by delivering 5 x 7.25 Gy = 36.25 Gy over two alternative time schedules:
Experimental Arm A: Over 9 days. Experimental Arm B: Over 28 days once-a-week, the same week-day. All patients will be followed up for at least 18 months to contribute to the analysis of the main endpoints of the study. With reference to the secondary endpoints, follow-up will be extended to 10 years.
Stopping rule: In order to avoid exposure of patients to a treatment that may be unsafe, acute GI and GU toxicity will be continuously monitored with the purpose of assisting in the decision of possibly interrupt recruitment in case of an alarming frequency.To this purpose, the procedure of Ivanova et al., 2005 will be applied.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- Onze Lieve Vrouwziekenhuis
-
-
-
-
-
Turku, Finland
- University Hospital
-
-
-
-
-
Ramat Gan, Israel
- Sheba Medical Center
-
-
-
-
-
Amsterdam, Netherlands
- VU University Medical Center
-
-
-
-
-
Porto, Portugal
- Portuguese Institut of Oncology
-
-
-
-
-
Barcelona, Spain
- Teknon Oncologic Institute
-
Madrid, Spain
- Hospital Universitario Sanchinarro
-
-
-
-
-
Geneva, Switzerland, 1211
- University Hospital
-
-
-
-
-
Istanbul, Turkey
- Neolife Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: >18
- WHO performance status ≤ 2
- Any patient where prophylactic lymph node irradiation is not required, i.e. risk of nodal microscopic involvement ≤ 20% (according to Roach et al (25):
"N+ (in %) = (Gleason score - 6) x 10 + 2/3 PSA at diagnosis)"
- T-stage: cT1-cT3a.
- Previous TURP is allowed provided there is at least 8 weeks interval with radiotherapy.
Combined hormonal treatment (Neoadjuvant-concomitant androgen deprivation, AD, for 6 months) is mandatory if two or more of the following tumour characteristics are present: ≥cT2c, Gleason 4+3, PSA >10 ng/ml, perineural invasion, and/or >1/3 of positive biopsies. RT shall be delivered between 2 and 3 months (+/- 1 week) after starting AD and according to the following chronologic sequence:
- Neoadjuvant AD for 2 months (30 days of bicalutamide 50mg qd, and a 3-month slow-releasing LH-RH analog to be started 15 days after initiating bicalutamide).
- Randomization at the end of the neoadjuvant AD period (2 months after starting AD).
- Planning RT (to be started within 1 month after randomization (i.e., between the 2nd and 3th month after initiating AD)
- Concomitant and adjuvant HT for 4 more months (a second 3-month slow-releasing LH-RH analog injection).
Exclusion Criteria:
- Inability to obtain a written informed consent
- Patient preference to be treated with one rather than the other treatment arm.
- WHO performance status > 2
- cT3b,cT4
- Gleason score ≥8
- Clinical N+ on metastases work-up or N+ risk >20% (Roach algorithm)
- Severe urinary obstructive symptoms (IPSS symptom index >19)
- Previous TURP less than 8 weeks before radiotherapy
- Previous prostate surgery other than TURP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 9 days
Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
|
Minimize radiation doses to surrounding area
Highly conformational dose distribution
Follow target by the use of fiducial markers and ERB
|
EXPERIMENTAL: 28 days
Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
|
Minimize radiation doses to surrounding area
Highly conformational dose distribution
Follow target by the use of fiducial markers and ERB
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance to treatment
Time Frame: up to 5 years
|
Tolerance to treatment (urinary, rectal, sexual): Acute (up to 90 days) and late (up to 5 years) toxicity follow-up according to NCI CTCAE version 3.0
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Quality of life
Time Frame: 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Quality of life (EORTC QLQ-C30, Prostate cancer module EORTC QLQ-PR25)
|
9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
2. Local failure
Time Frame: 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Assessed by digital rectal examination (DRE).
MRI or PET-CT with choline or acetate may be a confirmatory option.
Biopsy confirmation is required for those patients with exclusive local failures and candidates for local salvage.
|
9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
3. Biochemical disease-free survival bDFS
Time Frame: 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Phoenix definition (PSA nadir + 2 ng/ml)
|
9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
4. Metastases-free survival
Time Frame: 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Outcomes 3 or 4 - investigations PET-CT choline
|
9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
5. Disease-specific survival
Time Frame: 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Alive/dead status, date and cause of death and prostate cancer disease status (outcomes 3/4 and 5).
|
9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Zilli, Dr, University Hospital, Geneva
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-196
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm of Prostate
-
Case Comprehensive Cancer CenterNational Institutes of Health (NIH)Not yet recruitingProstate Cancer | Malignant Neoplasm of Prostate | Secondary Malignant Neoplasm of ProstateUnited States
-
National Taiwan University HospitalRecruitingBiochemical Relapse Fo Malignant Neoplasm of ProstateTaiwan
-
Mayo ClinicRecruitingPrimary Malignant Neoplasm of Prostate (Diagnosis)United States
-
Prof. Dr. med. Christian GratzkeMerck Sharp & Dohme LLCRecruitingUrologic Cancer | Biochemical Recurrence of Malignant Neoplasm of ProstateGermany
-
Sahlgrenska University Hospital, SwedenThe Swedish Research Council; Sjöbergstiftelsen; VGregionRecruitingGynecologic Cancer | Malignant Neoplasm | Malignant Neoplasm of Large Intestine | Malignant Neoplasm of Colon | Malignant Neoplasm of Prostate | Malignant Neoplasm of Rectum | Malignant Neoplasm of Anus | Malignant Neoplasm of Urinary Bladder | Malignant Neoplasm of Cervix | Malignant Neoplasm of OvarySweden
-
Tata Medical CenterCompletedMalignant Neoplasm of Oropharynx Stage III | Malignant Neoplasm of Larynx Stage III | Malignant Neoplasm of Hypopharynx Stage III | Malignant Neoplasm of Oropharynx Stage IVa | Malignant Neoplasm of Oropharynx Stage IVb | Malignant Neoplasm of Larynx Stage IV | Malignant Neoplasm of Hypopharynx... and other conditionsIndia
-
Clarity Pharmaceuticals LtdActive, not recruitingBiochemical Recurrence of Malignant Neoplasm of ProstateUnited States
-
Clarity Pharmaceuticals LtdCompletedBiochemical Recurrence of Malignant Neoplasm of ProstateUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditionsUnited States
-
University of UtahActive, not recruitingProstate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Recurrent Prostate Carcinoma | Oligometastasis | PSA FailureUnited States
Clinical Trials on Intensity modulated radiation therapy
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingAdult Soft Tissue SarcomaCanada, United States, Belgium
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck CarcinomaUnited States
-
Institut Cancerologie de l'OuestCompletedCervical Cancer | Prostate Cancer | Anal Canal CancersFrance
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic DiseaseUnited States
-
University Health Network, TorontoOntario Cancer Research NetworkCompleted
-
Xiangya Hospital of Central South UniversityRecruitingNasopharyngeal CarcinomaChina
-
Alberta Health servicesCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States